TUESDAY, Dec. 23, 2014 (HealthDay News) -- The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated intra-abdominal infections and complicated urinary tract infections.
The approval for intra-abdominal infections is for use of Zerbaxa in combination with another drug, metronidazole, the agency said in a news release. The approval for urinary tract infection includes pyelonephritis.
Zerbaxa is the fourth antibiotic to be FDA approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid), and Orbactiv (oritavancin).
The drug's label includes a warning about decreased effectiveness among people with renal impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache, and pyrexia.
Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.
More Information
